2015 Chronic Lymphocytic Leukemia (CLL) Pulse
2015 Chronic Lymphocytic Leukemia (CLL) Pulse
$599.00
We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.
Publisher: BioMedTracker
- Description
- Contents
- Samples
Overview
We performed a 5-question survey of 22 hematology-oncology specialists in the U.S. to gain insight on current prescribing practices for Chronic Lymphocytic Leukemia (CLL). Topics covered in this survey include:
- Current usage of monoclonal antibodies and oral kinase inhibitors for CLL treatment
- Comparison of expected future prescribing practices with predicted 2014 usage patterns from a December 2013 survey
- Drugs covered include: Imbruvica (ibrutinib, PCYC/JNJ), Zydelig (idelalisib, GILD), venetoclax/ABT-199 (ABBV and Roche), Gazyva (obinutuzumab, Roche), and others
BioMedTracker Survey
Chronic Lymphocytic Leukemia (CLL) #2: Drug Usage and Reimbursement
Breakdown of Surveyed Hematology-Oncology Specialists
Question #1:
Of the CLL patients you saw in the last 3 months, how many were at the following stages of treatment? [numerical free response]
Question #2:
Approximately what percentage of your CLL patients have the following types of medical insurance as their primary coverage? [numerical free response, answers must sum to 100%]
Question #3:
In the last 3 months, how many of your patients received the following treatment in the given lines of treatment? [numerical free response]
Question #4:
What are your impressions of reimbursement for ibrutinib in the following treatment groups, based on your experience with patients in your practice? [grid single-answer]
Question #5
What are your impressions of reimbursement for idelalisib+rituximab in the following treatment groups, based on your experience with patients in your practice? [grid single-answer]
Appendix: Oral TKI Market Opportunity by Indication
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview 
Sign up to the